This project aims to detect novel biomarkers from preoperative and early postoperative serum and urine samples of patients to screen and analyze the risk factors for predicting adverse postoperative renal outcomes in high-risk patients in cardiac surgery.
This project will prospectively collect all high-risk individuals who underwent cardiac surgery, collect medical history, laboratory data and specimen test results, and test biomarkers in blood and urine specimens. Previously identified candidate biomarkers include the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR), galectin-9 (Gal-9), perilipin-2 (Plin2), CCL-20 and CCN family member 1, among others. The occurrence of postoperative AKI will be the primary endpoint of the study. The variable factors that can be used to predict and warn the main research endpoints at an early stage were screened through methods such as logistic regression, and their non-inferiority compared with traditional markers was tested. This study will facilitate early clinical identification and early warning of AKI, early implementation of preventive measures and intervention strategies, thereby improving the prognosis of patients and improve the overall safety and success rate of cardiac surgery.
Study Type
OBSERVATIONAL
Enrollment
319
The management for AKI patients were performed by implementing a standard care "bundle" suggested by the Kidney Disease Improving Global Outcome (KDIGO) guideline.
Zhongshan hospital, Fudan university
Shanghai, Shanghai Municipality, China
Zhongshan hospital
Shanghai, Shanghai Municipality, China
AKI occurrence within 7 days
AKI was defined based on the Kidney Disease Improving Global Outcomes (KDIGO) criteria.
Time frame: 7 days
Moderate and severe AKI occurrence within 7 days
Stage 2 and stage 3 AKI based on KDIGO criteria.
Time frame: 7 days
AKI occurrence within 3 days
AKI was defined based on the Kidney Disease Improving Global Outcomes (KDIGO) criteria.
Time frame: 3 days
Major adverse kidney events
MAKE at discharge MAKE was defined as the composite of≥25% loss in estimated glomerular filtration rate (eGFR), dialysis, or death. Estimated GFR was calculated from serum creatinine using the MDRD equation.
Time frame: Perioperative
Receipt of renal replacement treatment
Patients received renal replacement therapy after being diagnosed with AKI.
Time frame: Perioperative
Mortality
Mortality at 30 days
Time frame: 30 days
length of stay in the ICU
length of stay in the ICU
Time frame: Perioperative
Length of stay in the hospital
Length of stay in the hospital
Time frame: Perioperative
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.